Shawn Davis
Chief Executive Officer Liberate Bio
Shawn Davis, Ph.D. is the CEO of Liberate Bio, a pioneering biotech company building the next generation of immune-cell therapies—delivered in vivo. With over 20 years of experience spanning startups to global biopharma leaders, Dr. Davis has built and led high-performance teams at AstraZeneca and Amgen, advancing programs from discovery through clinical development. A recognized expert in drug delivery, he has authored foundational research, holds over 20 U.S. patents, and chairs multiple industry-leading conferences. He is known for bridging scientific innovation with commercial strategy to transform therapeutic possibilities into patient impact.
Seminars
Wednesday 9th September 2026
Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
11:40 am
- Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
